| 摘要: |
| 目的:评价并比较阿立哌唑与利培酮治疗儿童孤独症谱系障碍(ASD) 合并注意缺陷多动障碍(ADHD) 的临床效果与安
全性。方法:将2021 年10 月至2024 年6 月在我院接受治疗的91 例ASD 合并ADHD 患儿采用随机数表法分为利培酮组45 例
(给予利培酮片治疗)和阿立哌唑组46 例(给予阿立哌唑片治疗)。比较两组神经递质[去甲肾上腺素(NE)、多巴胺(DA)、5-
羟色胺(5-HT)]、金属硫蛋白3(MT3)、脑电图检查结果、注意缺陷/ 多动评定量表(ADHD-RS)评分、康纳斯不注意缺陷-冲动因
子(CRSR-H)评分、孤独症儿童行为检查量表(ABC)评分、不良事件发生率。结果:两组治疗6、12 周的NE、DA、MT3 较治疗前
升高,5-HT 较治疗前降低(P<0. 05)。阿立哌唑组治疗6 周的NE、DA、MT3 高于利培酮组,5-HT 低于利培酮组( P<0. 05)。两
组治疗6、12 周的β 波较治疗前升高,θ 波较治疗前降低(P<0. 05)。阿立哌唑组治疗6 周的β 波高于利培酮组,θ 波低于利培
酮组(P<0. 05)。两组治疗6、12 周相关症状评分较治疗前降低(P<0. 05)。阿立哌唑组治疗6 周的ADHD-RS 评分、CRSR-H 评
分、ABC 评分低于利培酮组(P<0. 05)。两组不良事件发生率比较差异无统计学意义( P>0. 05)。结论:阿立哌唑治疗ASD 合
并ADHD 患儿可达到与利培酮相似效果,但阿立哌唑起效时间更快。 |
| 关键词: 阿立哌唑 孤独症谱系障碍 利培酮 注意缺陷多动障碍 神经递质 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2025.06.002 |
|
| 基金项目: |
|
| Clinical Comparative Study of Aripiprazole and Risperidone in the Treatment of Children with AutismSpectrum Disorder Complicated with Attention Deficit Hyperactivity Disorder |
| Xu Xianjia, Liu Di, Liu Tanglong |
| (Ningbo Mental Hospital, Zhejiang Ningbo 315000, China) |
| Abstract: |
| Objective: To evaluate and compare the clinical efficacy and safety of aripiprazole and risperidone in the treatment of
children with autism spectrum disorder (ASD) complicated with attention deficit hyperactivity disorder (ADHD). Methods: From Oct.
2021 to Jun. 2024, ninety-one children with ASD complicated with ADHD admitted into our hospital were divided into 45 cases in the
risperidone group (treated with risperidone tablets) and 46 cases in the aripiprazole group (treated with aripiprazole tablets) by the
random number table method. Neurotransmitters such as norepinephrine (NE), dopamine (DA) and 5-hydroxytryptamine (5-HT),
metallothionein 3 (MT3), electroencephalography (EEG), Attention-Deficit/ Hyperactivity Rating Scale (ADHD-RS) score, Connors’
Reaction to Inattention-Deficit-Hyperactivity Factor (CRSR-H) score, Autistic Children’s Behavioral Checklist (ABC) score, and the
incidence of adverse events were compared between two groups. Results: The levels of NE, DA and MT3 in both groups after 6 and 12
weeks of treatment increased compared with those before treatment, while the level of 5-HT decreased compared with that before
treatment (P<0. 05). The levels of NE, DA and MT3 in the aripiprazole group after 6 weeks of treatment were higher than those in the
risperidone group, while the level of 5-HT was lower than that in the risperidone group (P<0. 05). The β waves in both groups after 6
and 12 weeks of treatment increased compared with those before treatment, and the θ wave decreased compared with that before
treatment (P<0. 05). The β wave in the aripiprazole group after 6 weeks of treatment was higher than that in the risperidone group, and
the θ wave was lower than that in the risperidone group (P<0. 05). The scores of related symptoms in two groups after 6 and 12 weeks
of treatment were lower than those before treatment (P<0. 05). The ADHD-RS score, CRSR-H score and ABC score of aripiprazole
group after 6 weeks of treatment were lower than those of risperidone group (P<0. 05). There was no statistically significant difference in
the incidence of adverse events between two groups (P>0. 05). Conclusion: In children with ASD and ADHD, aripiprazole has similar
effects to risperidone, but aripiprazole has a faster onset of action. |
| Key words: aripiprazole autism spectrum disorder risperidone attention deficit hyperactivity disorder neurotransmitters |
